๐Ÿ”ฌDeep Research

VKTX โ€” Viking Therapeutics ยท catalysts, narrative & risks

ยท22 sourcesVKTX forecast โ†’

Viking Therapeutics (VKTX) โ€” Point-in-Time Research Brief (as of 2026-11-11)

Overview

Viking Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, focused on metabolic and endocrine disorders with an obesity-centric pipeline [1], [2]. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations [1], [2], [20]. It trades on the Nasdaq and is categorized among biotech names [14].

Recent Catalysts (roughly Augโ€“Nov 2026)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’